rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Rockwell Medical, Inc.

RMTI · Nasdaq

Health CareBiotechnologyNot moving yet

RMTI stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 4.9% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 52
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$19K
Officials’ trades on record
0
Institutions holding
35 (-17)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$64K$0$88KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months4
Buyers · sellers0 · 4
WhoDidSharesTraded
Mark StrobeckPresident and CEOsold1,000at $8.421 Oct 2026filed 5 Oct 2026
Jesse NeriSVP and CFOsold886at $0.83552 Jan 2026filed 5 Jan 2026
Heather HunterChief Operating Officersold2,868at $0.83552 Jan 2026filed 5 Jan 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders35-17 on the quarter
New · exited5 · 22
Reported value$1.9M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 20261,229,888$678K-2,255,490−64.7%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 2026364,061$214K-1,057,038−74.4%
RENAISSANCE TECHNOLOGIES LLCreduced · filed 13 Aug 2026359,672$198K-279,448−43.7%
JANE STREET GROUP, LLCadded · filed 14 Aug 2026245,229$135K+136,039+124.6%
VANGUARD FIDUCIARY TRUST COreduced · filed 13 Aug 2026232,660$128K-515,664−68.9%
Wealthspire Advisors, LLCunchanged · filed 11 Aug 2026151,838$84K00.0%
BlackRock, Inc.reduced · filed 7 Aug 2026144,756$80K-98,047−40.4%
STATE STREET CORPreduced · filed 7 Aug 2026100,904$56K-526,300−83.9%
NORTHERN TRUST CORPreduced · filed 13 Aug 202691,862$51K-205,915−69.2%
UBS Group AGreduced · filed 13 Aug 202670,010$39K-646,669−90.2%
31 Mar 2023 – 30 Jun 2026
254361Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Mark Strobeck Company insiderPresident and CEO · last 1 Oct 20260 · 7
Allen Nissenson Company insiderDirector · last 1 Jul 20260 · 0
Heather Hunter Company insiderChief Operating Officer · last 1 Jul 20260 · 2
Jesse Neri Company insiderSVP and CFO · last 1 Jul 20260 · 5
Joan Lau Company insiderDirector · last 1 Jul 20260 · 0
John G. Cooper Company insiderDirector · last 1 Jul 20260 · 1
Joseph H. Dawson Company insiderDirector · last 1 Jul 20260 · 0
Megan C. Timmins Company insiderEVP, CLO & Secretary · last 1 Jul 20260 · 0
Robert S. Radie Company insiderDirector · last 1 Jul 20260 · 0
Timothy Chole Company insiderSVP and CCO · last 1 Jul 20260 · 6
Andrea Heslin Smiley Company insiderDirector · last 20 May 20250 · 0
Mark H. Ravich Company insiderDirector · last 20 May 20250 · 1

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202516.9%
Operating profit marginFY 2025 · to 31 Dec 2025-6.8%
Free cash flow marginFY 2025 · to 31 Dec 2025-1.7%
Return on capital employedFY 2025 · to 31 Dec 2025-9.9%
Debt to equityFY 2025 · to 31 Dec 20250.24×
Research spendFY 2025 · to 31 Dec 20250.0%
Share count trendFY 2025 · to 23 Mar 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$10.7M
Free cash flowFY 2025 · to 31 Dec 2025−$1.2M

Analyst forecasts

No analyst forecasts yet.